Journal of cardiology最新文献

{"title":"JCS/JCC/JACR/JATS 2024 guideline on cardiovascular practice with consideration for diversity, equity, and inclusion","authors":"Yayoi Tetsuou Tsukada, Chizuko Aoki-Kamiya, Atsushi Mizuno, Atsuko Nakayama, Tomomi Ide, Rie Aoyama, Junko Honye, Katsuyuki Hoshina, Toshimi Ikegame, Koki Inoue, Yasuko K. Bando, Masaharu Kataoka, Naoki Kondo, Koji Maemura, Miyuki Makaya, Naoya Masumori, Asako Mito, Mizuho Miyauchi, Aya Miyazaki, Yukiko Nakano, Hitonobu Tomoike","doi":"10.1016/j.jjcc.2025.03.002","DOIUrl":"10.1016/j.jjcc.2025.03.002","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 510-574"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial differences in diuretic therapy, B-type natriuretic peptide values, and prognosis in acute heart failure","authors":"Yu Horiuchi ,&nbsp;Yuya Matsue MD, PhD ,&nbsp;Nicholas Wettersten ,&nbsp;Shogo Oishi ,&nbsp;Eiichi Akiyama ,&nbsp;Satoshi Suzuki ,&nbsp;Masayoshi Yamamoto ,&nbsp;Keisuke Kida ,&nbsp;Takahiro Okumura ,&nbsp;Takeshi Kitai ,&nbsp;Dirk J. van Veldhuisen ,&nbsp;Alan Maisel ,&nbsp;Patrick T. Murray ,&nbsp;Tohru Minamino","doi":"10.1016/j.jjcc.2025.01.013","DOIUrl":"10.1016/j.jjcc.2025.01.013","url":null,"abstract":"<div><h3>Background</h3><div>Whether variability of B-type natriuretic peptide (BNP) values between races affects its clinical integration as a marker for congestion and predictor of prognosis in acute heart failure (AHF) remains unknown. We aimed to investigate the relationship between diuretic therapy, change in BNP value, and prognosis in AHF in relation to racial differences.</div></div><div><h3>Methods</h3><div>This analysis combined data from the AKINESIS and REALITY-AHF studies. We included White, Black, and Asian individuals admitted with AHF requiring intravenous diuretic therapy. We examined the relative change in BNP values at 48 h post hospital admission, and its association with diuretic therapy and one-year mortality.</div></div><div><h3>Results</h3><div>Of 1380 participants, 29 % were White, 12 % were Black, and 58 % were Asian. Admission BNP values were highest in Black, followed by Asian and White individuals. After adjusting for confounding factors, Black individuals had significantly higher admission BNP values compared to White individuals. During the first 48 h of hospitalization, Asian individuals received the lowest diuretic dose but demonstrated the greatest diuretic response and BNP decrease. After adjustment for confounding factors, Asian individuals were more likely to have a BNP decrease compared to White individuals. Higher admission BNP values predicted higher one-year mortality in White and Asian but not in Black individuals (<em>p</em> for interaction = 0.021). BNP decrease was associated with a lower one-year mortality without a significant interaction by race.</div></div><div><h3>Conclusions</h3><div>In AHF patients, admission BNP was higher in Black, and its decrease after diuretic therapy was greater in Asian individuals. A BNP decrease predicted a better prognosis, regardless of race.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 486-493"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-echocardiography: Current status and future direction","authors":"Yuki Sahashi MD, MSc ,&nbsp;David Ouyang MD ,&nbsp;Hiroyuki Okura MD, PhD, FJCC ,&nbsp;Nobuyuki Kagiyama MD, PhD","doi":"10.1016/j.jjcc.2025.02.005","DOIUrl":"10.1016/j.jjcc.2025.02.005","url":null,"abstract":"<div><div>Echocardiography, which provides detailed evaluations of cardiac structure and pathology, is central to cardiac imaging. Traditionally, the assessment of disease severity, treatment effectiveness, and prognosis prediction relied on detailed parameters obtained by trained sonographers and the expertise of specialists, which can limit access and availability. Recent advancements in deep learning and large-scale computing have enabled the automatic acquisition of parameters in a short time using vast amounts of historical training data. These technologies have been shown to predict the presence of diseases and future cardiovascular events with or without relying on quantitative parameters. Additionally, with the advent of large-scale language models, zero-shot prediction that does not require human labeling and automatic echocardiography report generation are also expected. The field of AI-enhanced echocardiography is poised for further development, with the potential for more widespread use in routine clinical practice. This review discusses the capabilities of deep learning models developed using echocardiography, their limitations, current applications, and research utilizing generative artificial intelligence technologies.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 458-464"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaboration between dyspnea clinic and primary care physicians to identify heart failure with preserved ejection fraction in the community: Results from the Maebashi City HF project","authors":"Naoki Yuasa MD ,&nbsp;Satoshi Ubukata MD ,&nbsp;Ryo Takayanagi MD ,&nbsp;Eiji Yamashita MD ,&nbsp;Keiji Hoshino MD ,&nbsp;Yuta Tani MSc ,&nbsp;Takashi Kawashima MD, PhD ,&nbsp;Hideki Ishii MD, PhD, FJCC ,&nbsp;Masaru Obokata MD, PhD","doi":"10.1016/j.jjcc.2025.01.001","DOIUrl":"10.1016/j.jjcc.2025.01.001","url":null,"abstract":"<div><h3>Background</h3><div>Despite increasing awareness in general practice, heart failure with preserved ejection fraction (HFpEF) remains under-diagnosed in the community due to diagnostic difficulties. Dedicated dyspnea clinics are responsible for diagnosing HFpEF and efficient referral from primary care physicians is the key to enhance its role.</div></div><div><h3>Methods</h3><div>This retrospective analysis was performed to assess the effectiveness of a one-year collaborative project between our dyspnea clinic and the Maebashi Medical Association. Primary care physicians were encouraged to screen patients at risk for HFpEF and refer them to the dyspnea clinic, where exercise stress echocardiography was utilized to enhance the identification of HFpEF. To evaluate the clinical value of the project, the data obtained were compared with data from the previous year without collaboration.</div></div><div><h3>Results</h3><div>The collaborative project was conducted between May 2023 and May 2024. The rate of patients referred from the city increased from 47 % during the previous year to 87 % during the collaborative period (<em>p</em> &lt; 0.0001). Most of the patients were referred by non-cardiologists (77 %). The prevalence of HFpEF diagnosis tended to increase from 32 % to 39 % after the collaborative project, while pulmonary causes of dyspnea tended to decrease from 21 % to 12 %. After a thorough evaluation at the dyspnea clinic, 98 % of referred patients were referred back to their referring physicians for further treatment and follow-up.</div></div><div><h3>Conclusions</h3><div>These data suggest the effectiveness of our approach to identify HFpEF in the community through collaboration between the dedicated dyspnea clinic and primary care physicians.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 480-485"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment in patients with heart failure: Physiopathology, clinical implications, and therapeutic considerations","authors":"Meng Li MD, PhD ,&nbsp;Junping Zhang MD, PhD ,&nbsp;Yue Hu MD, PhD ,&nbsp;Yue Zhang MM","doi":"10.1016/j.jjcc.2025.02.007","DOIUrl":"10.1016/j.jjcc.2025.02.007","url":null,"abstract":"<div><div>Cognitive impairment (CI) is a significant comorbidity in individuals with heart failure (HF). A substantial number of patients with HF may experience CI, which can present as deficits in attention, memory, executive function, and processing speed. HF patients with CI tend to have reduced functional independence, self-care capabilities, medication adherence and decision-making ability, along with more frequent rehospitalizations, and an increased risk of mortality. Currently, there is no established gold standard diagnostic tool or follow-up strategy for assessing CI in patients with HF. There has been an increasing recognition of the complex bidirectional relationship between HF and CI. However, the exact pathological mechanisms of CI in HF need further in-depth investigation. This review aims to explore the current epidemiological status of CI in patients with HF, the relationship between HF and cognitive dysfunction, the pathological mechanisms involved, as well as the early screening, diagnosis, and management issues for HF patients with CI. It also discusses prevention and intervention strategies. The objective is to provide a scientific basis for the clinical diagnosis, management, and treatment of CI in HF, while proposing future research directions to advance this field.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 465-472"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin inhibitor: A retrospective analysis in 200 patients","authors":"Haruna Inoue MD ,&nbsp;Kenzo Uzu MD ,&nbsp;Yusuke Fukuyama MD ,&nbsp;Yoshinori Nagasawa MD ,&nbsp;Kiyohiro Hyogo MD ,&nbsp;Yasushi Shimokawa MD ,&nbsp;Hideaki Okubo MD ,&nbsp;Hiroki Shimizu MD","doi":"10.1016/j.jjcc.2025.02.006","DOIUrl":"10.1016/j.jjcc.2025.02.006","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 505-506"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-hospital mortality and risk factors in critically ill patients with hypertrophic cardiomyopathy","authors":"Zhiyuan Ma MD, PhD,&nbsp;Jamshid Shirani MD","doi":"10.1016/j.jjcc.2025.01.003","DOIUrl":"10.1016/j.jjcc.2025.01.003","url":null,"abstract":"<div><h3>Background</h3><div>Hypertrophic cardiomyopathy (HCM) is a common genetic disease with estimated prevalence of 0.2–0.5 %. Contemporary management has substantially improved HCM outcomes. However, the impact of HCM on critically ill patients admitted to intensive care units (ICU) has not been well studied.</div></div><div><h3>Methods</h3><div>Unmatched and propensity score matched patients with or without HCM were examined in the MIMIC-IV database and compared for mortality, morbidity, and length of stay. Multivariable logistic regression was used to identify risk factors associated with in-hospital mortality in patients with HCM.</div></div><div><h3>Results</h3><div>Of 51,926 critically ill patients, 165 (0.32 %) were also diagnosed with HCM. Compared with those without HCM, patients with HCM had higher body mass index, higher rates of heart failure, atrial fibrillation, and chronic renal disease, and more often had implantable cardioverter defibrillators. There were no significant differences in in-hospital mortality (10.3 % vs 10.2 %) or length of stay (9.3 ± 9.6 vs 9.3 ± 1 0.6 days) between the two groups. Similar results were obtained in propensity score matched patients with or without HCM. Univariable analyses identified respiratory failure, sepsis, use of vasopressors, and circulatory support devices as predictors of in-hospital mortality in adults with HCM. In multivariable logistic regression analysis, respiratory failure and use of vasopressors and circulatory support devices were the predictors of in-hospital mortality in HCM patients.</div></div><div><h3>Conclusions</h3><div>Presence of HCM did not affect in-hospital mortality in critically ill patients, but the need for vasopressors and circulatory support devices predicted worse in-hospital mortality among critically ill patients with HCM.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 500-501"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural instability of ryanodine receptor 2 causes endoplasmic reticulum (ER) dysfunction as well as sarcoplasmic reticulum (SR) dysfunction","authors":"Hitoshi Uchinoumi MD, PhD ,&nbsp;Yoshihide Nakamura MD, PhD ,&nbsp;Takeshi Suetomi MD, PhD ,&nbsp;Takashi Nawata MD, PhD ,&nbsp;Masafumi Fujinaka MD ,&nbsp;Shigeki Kobayashi MD, PhD, FJCC ,&nbsp;Takeshi Yamamoto MD, PhD ,&nbsp;Masafumi Yano MD, PhD, FJCC ,&nbsp;Motoaki Sano MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.02.003","DOIUrl":"10.1016/j.jjcc.2025.02.003","url":null,"abstract":"<div><div>The type 2 ryanodine receptor (RyR2) is a giant Ca²⁺ (Ca)-releasing channel on the sarcoplasmic reticulum (SR) membrane, with subunits composed of 5000 amino acids constituting a homotetrameric channel. The N-terminal (1−220) and central (2300–2500) domain interactions (inter-subunit zipping interfaces) within RyR2 are located in close proximity to each other between different neighboring subunits and play an important “cornerstone” role in maintaining the tetrameric structure of RyR2. External stress such as oxidative stress causes Ca leak by destabilizing RyR2 (instability of the tetrameric structure) due to domain unzipping between N-terminal (1–220) and central (2300–2500) domains, followed by dissociation of calmodulin (CaM: binds to the RyR2 and stabilize RyR2) from RyR2. Ca leak from SR causes arrhythmias and myocardial dysfunction.</div><div>RyR2 is also present in the endoplasmic reticulum (ER), thus it is not surprising that undesired Ca release from RyR2 on the ER is closely associated with various diseases involving ER dysfunction such as neurodegenerative diseases, diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, and autoimmune diseases. Pharmacological or genetic (point mutations within RyR2 that increase CaM-RyR2 affinity: knock-in RyR2-V3599K) RyR2 structural stabilization has shown potential therapeutic effects not only for SR failure-related diseases (malignant hyperthermia, arrhythmia, and heart failure) but also for ER failure-related disease. RyR2-stabilizers may function as a panacea for aging-related diseases.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 450-457"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in clinical practice for wild-type transthyretin amyloid cardiomyopathy from Kochi amyloidosis cohort: Impact of a new guideline and diagnosis and treatment strategy in Japan","authors":"Yuri Ochi MD,&nbsp;Toru Kubo MD, FJCC,&nbsp;Yuichi Baba MD,&nbsp;Kazuya Miyagawa MD,&nbsp;Tatsuya Noguchi MD,&nbsp;Takayoshi Hirota MD,&nbsp;Naohito Yamasaki MD,&nbsp;Hiroaki Kitaoka MD, FJCC","doi":"10.1016/j.jjcc.2024.11.011","DOIUrl":"10.1016/j.jjcc.2024.11.011","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 447-449"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use","authors":"Masahiro Ieko MD, PhD ,&nbsp;Kazumasa Ohmura MD, PhD ,&nbsp;Sumiyoshi Naito MT, PhD ,&nbsp;Mika Yoshida MT ,&nbsp;Osamu Kumano PhD","doi":"10.1016/j.jjcc.2025.02.013","DOIUrl":"10.1016/j.jjcc.2025.02.013","url":null,"abstract":"<div><div>Thrombosis is a potentially fatal condition for which various anticoagulant therapies have been used for prevention and treatment. However, bleeding events remain a concern with all anticoagulant drugs. Recent evidence suggests that inhibiting coagulation factor XI (FXI) and activated FXI (FXIa) plays a greater role in the formation of pathological thrombi in thrombosis than in normal hemostatic thrombi, allowing for the potential to address these two events separately. Consequently, FXI/XIa inhibition has become the focus of anticoagulant drug research, leading to the development of numerous FXI-targeting compounds with diverse mechanisms of action. Herein, we aimed to review FXI/FXIa inhibitors under development, discussing the role of FXI in the coagulation reaction and the advantages and disadvantages associated with its deficiency. The results of a Phase II study showed that FXI/XIa inhibitors provide efficacy comparable to that of low molecular weight heparin therapy while reducing clinically significant bleeding events. Additionally, in a study of patients with atrial fibrillation, FXI/XIa inhibitors reduced bleeding events compared to those with direct oral anticoagulants. Furthermore, when combined with antiplatelet therapy, FXI/XIa inhibitors did not significantly increase bleeding risk in non-cardioembolic stroke or acute coronary syndrome. However, conflicting trial results have also been reported, highlighting the difficulty in assessing the clinical benefit of FXI/XIa inhibitors in different clinical settings, such as atrial fibrillation and acute myocardial infarction. Future large, well-designed Phase III studies are needed to evaluate the safety and efficacy of FXI/XIa inhibitors across diverse populations requiring antithrombotic therapy.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 473-479"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}